Found: 8
Select item for more details and to access through your institution.
Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 103, doi. 10.1007/s00280-023-04504-z
- By:
- Publication type:
- Article
Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 121, doi. 10.1007/s00280-022-04494-4
- By:
- Publication type:
- Article
Value of whole-body dynamic <sup>18</sup>F-FMISO PET/CT Patlak multi-parameter imaging for evaluating the early radiosensitizing effect of oleanolic acid on C6 rat gliomas.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 133, doi. 10.1007/s00280-022-04502-7
- By:
- Publication type:
- Article
Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [<sup>14</sup>C] SHC014748M in healthy Chinese subjects following oral administration.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 143, doi. 10.1007/s00280-022-04493-5
- By:
- Publication type:
- Article
The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 157, doi. 10.1007/s00280-022-04499-z
- By:
- Publication type:
- Article
A bioequivalence study of trifluridine/tipiracil tablets in Chinese metastatic colorectal cancer patients under fed conditions.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 167, doi. 10.1007/s00280-022-04501-8
- By:
- Publication type:
- Article
Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 179, doi. 10.1007/s00280-022-04500-9
- By:
- Publication type:
- Article
The CNS-penetrating taxane drug TPI 287 potentiates antiglioma activity of the AURKA inhibitor alisertib in vivo.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2023, v. 91, n. 2, p. 191, doi. 10.1007/s00280-023-04503-0
- By:
- Publication type:
- Article